CCX832 is the fourth and final drug candidate discovered and developed by ChemoCentryx under its alliance with GlaxoSmithKline (GSK) to identify molecules targeting four specific chemokine and chemoattractant receptors.
ChemoCentryx said that the initiation of this Phase I clinical trial triggered a $10m milestone payment from GSK.
ChemoCentryx president and CEO Thomas Schall said with the successful conclusion of the discovery phase of our GSK alliance, they are intensifying and expanding their efforts in the other ongoing programs that are entirely outside the GSK alliance.
"These programs include a novel drug targeting the chemokine receptor CCR2, which has just successfully completed a Phase 2 clinical trial and a cancer program targeting the receptor CXCR7, which was discovered by ChemoCentryx scientists," Schall said.
"In addition, we are advancing programs in liver and kidney disease and in the next generation of medicines for inflammatory bowel disease, all of which offer vast opportunities in largely unmet medical needs."